Moderna begins phase 3 trial of mRNA bird flu vaccine

April 21, 2026 7:01 PM

Moderna Inc. (NASDAQ: MRNA) has started dosing participants in a phase 3 clinical trial of its investigational mRNA-based H5 pandemic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found